The location of KIT and PDGFRA gene mutations in gastrointestinal stromal tumours is site and phenotype associated
- 25 May 2005
- journal article
- Published by BMJ in Journal of Clinical Pathology
- Vol. 58 (6) , 634-639
- https://doi.org/10.1136/jcp.2004.021766
Abstract
Aims: To assess the relation between KIT and PDGFRA mutations and the site of origin, histological phenotype, and pathomorphologically determined risk assessment in gastrointestinal stromal tumours (GISTs). Methods: A series of 83 clinicopathologically characterised GISTs from 79 patients was analysed for KIT and PDGFRA mutations by polymerase chain reaction amplification, single strand conformation polymorphism analysis, and direct DNA sequencing. Results: KIT or PDGFRA mutations were found in 57 and 11 GISTs, respectively. Most KIT mutations involved exon 11 (46 cases), followed by exon 9 (10 cases). The PDGFRA mutations mostly affected exon 18 (eight cases), followed by exon 12 (three cases). There was a significant association between KIT exon 9 mutations and an intestinal origin of GISTs, and between PDGFRA mutations and gastric origin of the tumours. In addition, the presence of PDGFRA mutations was significantly associated with epithelioid/mixed histology, as was the absence of identified receptor tyrosine kinase mutations. Vice versa, KIT exon 11 mutations were almost exclusively found in spindle cell GISTs. Furthermore, the presence of any KIT and PDGFRA mutations and the presence of KIT mutations alone were significantly associated with high risk/malignant GISTs. Conclusions: The location of KIT and PDGFRA mutations in GISTs is associated with the site of origin and histological phenotype. Genotyping of GISTs may be a helpful additional parameter in determining the biological profile of these tumours.Keywords
This publication has 34 references indexed in Scilit:
- Prognostic Significance of c-kit Mutation in Localized Gastrointestinal Stromal TumorsClinical Cancer Research, 2004
- Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma GroupEuropean Journal Of Cancer, 2004
- Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal TumorJournal of Clinical Oncology, 2003
- Gastrointestinal Stromal Tumors with Internal Tandem Duplications in 3′ End of KIT Juxtamembrane Domain Occur Predominantly in Stomach and Generally Seem to Have a Favorable CourseLaboratory Investigation, 2003
- Gastrointestinal stromal tumors in a mouse model by targeted mutation of the Kit receptor tyrosine kinaseProceedings of the National Academy of Sciences, 2003
- Prognostic Value ofKITMutation Type, Mitotic Activity, and Histologic Subtype in Gastrointestinal Stromal TumorsJournal of Clinical Oncology, 2002
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002
- Chromosomal aberrations in malignant gastrointestinal stromal tumorsCancer Genetics and Cytogenetics, 2001
- Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal TumorsScience, 1998
- Structure, Organization, and Transcription Units of the Human α-Platelet-Derived Growth Factor Receptor Gene, PDGFRAGenomics, 1995